



Declaration on compliance with the ENCePP Code of Conduct for ENCePP Studies¹

The (primary) lead investigator and a person authorised to sign on behalf of the coordinating study entity hereby declare for the purpose of conducting the study <include here study name and identifier/reg.no.>

ALCAPONE - ENCePP/SDPP/13031

- to follow the rules and principles for the independent and transparent conduct of pharmacoepidemiological and pharmacovigilance studies of the current version of the ENCePP Code of Conduct²;
- to inform the ENCePP Secretariat, without delay, of any change or decision to change that constitutes a deviation from the provisions of this Code.

It is of note that the (primary) lead investigator and the person authorised to sign on behalf of the coordinating study entity may be identical.

Name of (primary) lead investigator: Nicholas Moore

Date: 05/04/2016 (dd/mm/yyyy)

Stamp (if applicable) and signature:


Service de Pharmacologie - Pr N. MOORE
Pharmaco-épidémiologie CIC Bordeaux CIC1401
Université de Bordeaux / CHU de Bordeaux
Inserm / Adera
Bât. Le Tondu - Case 41 - 146 rue Léo Saignat
33076 Bordeaux cedex

Name of the coordinating study entity: Bordeaux PharmacoEpi

Address:

Université de Bordeaux
Service de Pharmacologie médicale
Batiment Le Tondu - case 41
146 rue Léo Saignat
33076 Bordeaux Cedex

Name of person authorised to sign on behalf of the coordinating study entity [if different from (primary) lead investigator]:

Date: (dd/mm/yyyy)

Stamp (if applicable) and signature:

The (primary) lead investigator should also complete, sign and date the Checklist of the ENCePP Code of Conduct for ENCePP Studies.

Electronic signatures or photocopies of the completed declaration and checklist will not be accepted.

¹ Complete the declaration on screen, then print, stamp (if applicable) and sign.

² Adopted Code and any revision thereof at the time of signature of the declaration.

[Reset Form](#)